louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06559384: Facilitators and Barriers to Dental Care in Head and Neck Cancer Patients
Official title: Facilitators and Barriers to Dental Care in Head and Neck Cancer Patients - Perspectives From Patients, Dentists, and Oncologists
Study type: OBSERVATIONAL
Overall status: ENROLLING_BY_INVITATION
Conditions: Behavior
Keywords: interviews
decision-making
Lead sponsor: University Medical Center Goettingen
Sponsor class: OTHER
First posted: 2024-08-19
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with head-neck cancer, dentists (general dentists and specialised dentists) who are working in clinics and private practices in Germany and oncologists (specialists in radiotherapy and specialists in otolaryngology) who are working in Germany

Brief summary: The aim of this study is to identify potential facilitators and barriers to dental care in head-neck cancer patients from the perspective of affected patients, dentists, and oncologists (specialists in radiotherapy and specialists in otolaryngology).

Detailed description: Patients as well as dentists and oncologists will be interviewed in semi-structured individual interviews. The interview guide used will align with the 14 domains of the Theoretical Domains Framework. Through qualitative content analysis, both facilitators and barriers to dental treatment for head-neck cancer patients will be identified.

Eligibility criteria: Inclusion Criteria:

* Patients with head and neck tumors whose health condition allows for the conduction of an interview
* Dentists practicing in Germany
* Specialists in otorhinolaryngology practicing in Germany
* Specialists in radiation therapy practicing in Germany

Exclusion Criteria:

* Missing consent for the study
* Health condition that does not allow the conduction of an interview

Primary outcomes:
measure: Questionnaire
timeFrame: 5 minutes
measure: Interview
timeFrame: 60 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Göttingen
country: Germany
facility: University Medical Center Göttingen
Study officials:
affiliation: University Medical Center Goettingen, Department of Preventive Dentistry, Periodontology and Cariology
name: Felix Marschner, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00130884: Peroral Levosimendan in Chronic Heart Failure
Official title: Effects of Peroral Levosimendan in the Prevention of Further Hospitalisations in Patients With Chronic Heart Failure. A Randomised, Phase II, Double-Blind, Placebo-Controlled, Multi-Centre, Parallel-Group Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Chronic Heart Failure
Heart Diseases
Keywords: levosimendan
chronic heart failure
oral administration
Lead sponsor: Orion Corporation, Orion Pharma
Sponsor class: INDUSTRY
First posted: 2005-08-16
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study will investigate the efficacy of oral levosimendan in patients with chronic New York Heart Association (NYHA) IIIb-IV heart failure (HF) using a composite end-point evaluating patient symptoms, morbidity and mortality. The patients are on treatment for at least 6 months.

Detailed description: The patients are randomised to 3 groups; higher or lower levosimendan dose group or placebo.

Eligibility criteria: Inclusion Criteria:

* Diagnosed chronic heart failure
* Severe symptoms (NYHA IIIb-IV)
* Optimal on-going oral treatment for HF
* Left ventricular ejection fraction less than or equal to 30%

Exclusion Criteria:

* Severe obstruction of ventricular outflow tracts
* Acute myocardial infarction within 30 days before screening
* Cardiac surgery or coronary angioplasty within 30 days before screening

Primary outcomes:
measure: Composite endpoint measuring symptoms, morbidity, mortality
Secondary outcomes:
Other outcomes:
Locations:
city: Helsinki
country: Finland
facility: Helsinki University Central Hospital
Study officials:
affiliation: Helsinki University Central Hospital, Finland
name: Markku S Nieminen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04296084: Upper Extremity Kinematics During Walking
Official title: Determination of Upper Extremity Kinematics During Walking in Healthy Individuals
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy
Lead sponsor: Hacettepe University
Sponsor class: OTHER
First posted: 2020-03-05
Enrollment: 47
Sex: ALL
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy individuals in the age of 20-40 years

Brief summary: Our aim is to investigate the upper extremity kinematics during walking in healthy individuals.

Detailed description: Determination of Upper Extremity Kinematics During Walking

Eligibility criteria: Inclusion Criteria:

* Between the ages of 20 and 40 years individuals
* Without any medical condition that would affect gait or arm swing

Exclusion Criteria:

* People with upper or lower limb asymmetry

Primary outcomes:
measure: Kinematic analysis
timeFrame: up to 20 weeks
Secondary outcomes:
measure: Time-Distance Characteristics of the Gait
timeFrame: up to 20 weeks
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Hacettepe University Faculty of Physical Therapy and Rehabilitation
state: Altındağ
Study officials:
affiliation: Hacettepe University
name: Ali İ Yalçın, MSc
role: PRINCIPAL_INVESTIGATOR
affiliation: Hacettepe University
name: Burcu Şahin, MSc
role: PRINCIPAL_INVESTIGATOR
affiliation: Hacettepe University
name: Dilara Onan, MSc
role: PRINCIPAL_INVESTIGATOR
affiliation: Hacettepe University
name: Mert Doğan, MSc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01124084: The Factors Affecting Intentions of Medical Staff to Use Personal Health Record in Northern Hospitals of Taiwan
Official title: The Factors Affecting Intentions of Medical Staff to Use Personal Health Record in Northern Hospitals of Taiwan
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy Subjects
Health Care Providers
Lead sponsor: Taipei Medical University WanFang Hospital
Sponsor class: OTHER
Collaborators: name: Taipei Medical University
First posted: 2010-05-14
Enrollment: 1800
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Health care providers from three hospitals in Taipei

Brief summary: Application of health information technology be able to solve a lot of problems of medical management, and effective actions to achieve the purpose of medical care. The "Personal Health Record" (PHR), so that patients can have, access and update their health records and share health information to a new healthcare provider can avoid the duplication of a clinic procedures, reduce medical costs and time, and can make an appointment online, tracking vaccinations, check drug allergy, master with health-related information such as exercise, diet condition, and have no time constraints to the hospital clinic. In the future, PHR is expected to reduce medical errors, reduce costs, effective use of medical resources. Purpose of this study is to understand the impact to the staff's attitude and intention when they use the PHR, and to explore the medical records of personal health awareness and intention to use the relevant factors, the research result will be a reference to government authority or medical institutions in order to promote personal health record system in Taiwan.

In this study, there will include the medical staff of three hospitals in Taipei, the Technology Acceptance Model (TAM model) based structured questionnaire will be used, questionnaire had tested by validity and reliability. The electronic questionnaires will be used, and apply the software SPSS and Amos17.0 descriptive and inferential statistical analysis.


Eligibility criteria: Inclusion Criteria:

* Health care provider
* Volunteer Subject
* Be able to understand the content of questionnaire

Exclusion Criteria:

- None

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Taipei Medical University WanFang Hospital
Study officials:
affiliation: Taipei Medical University Department of Health Care
name: Hsyien-Chia Wen, Ph.D.
role: STUDY_CHAIR
References:
Clinical trial NCT06737679: The Effects of Body Scan on Enteroception in Patients With Heart Failure
Official title: The Effects of Body Scan on Enteroception in Patients With Heart Failure: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Heart Failure
Keywords: Heart failure
Enteroception
Body scan
Mindfullness
Self-care monitoring
Lead sponsor: Centro Cardiologico Monzino
Sponsor class: OTHER
Collaborators: name: University of Rome Tor Vergata
name: Bicocca Universiy of Milano, Milan, Italy
name: American Holistic Nurses Association (AHNA)
First posted: 2024-12-17
Enrollment: 110
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The study aims to explore the effects of body scan on enteroception in people with heart failure


Eligibility criteria: Inclusion Criteria:

* Diagnosed with Heart Failure
* Italian speaking
* Willing to sign the Informed Consent Form

Exclusion Criteria:

* Cognitive Impairment documented in the medical records

Primary outcomes:
measure: Enteroceptive sensibility
timeFrame: At 1 month after the end of the body scan intervention
Secondary outcomes:
measure: Enteroceptive Sensibility
timeFrame: At 3, 6, and 9 month after the end of the intervention
measure: Enteroceptive Accuracy
timeFrame: At baseline, 1, 3, 6, and 9 months after the end of the intervention
measure: Enteroceptive Awareness
timeFrame: At baseline, after 1, 3, 6, and 9 months after the end of the intervention
measure: Symptoms Perception
timeFrame: At baseline, 1, 3, 6, and 9 months after the end of the intervention
measure: Generic Quality of Life
timeFrame: At baseline, 1, 3, 6, and 9 months after the end of the intervention
measure: Heart Failure Specific Quality of Life
timeFrame: At baseline, 1, 3, 6, and 9 months after the end of the intervention
measure: Self-care
timeFrame: At baseline, 1, 3, 6, and 9 months after the end of the intervention
measure: Self-care Self-efficacy
timeFrame: At baseline, 1, 3, 6, and 9 months after the end of the intervention
measure: Anxiety
timeFrame: At baseline, 1, 3, 6, and 9 months after the end of the intervention
measure: Depression
timeFrame: At baseline, 1, 3, 6, and 9 months after the end of the intervention
measure: Alexithymia
timeFrame: At baseline, 1, 3, 6, and 9 months after the end of the intervention
measure: Emotional Regulation
timeFrame: At baseline, 1, 3, 6, and 9 months after the end of the intervention
Other outcomes:
Locations:
city: Milan
country: Italy
facility: Cardiology Center Monzino IRCCS
city: Milan
country: Italy
facility: IRCCS Cardiology Center Monzino
Study officials:
References:
Clinical trial NCT02222779: Quantification of Transition Metals
Official title: Quantification of Transition Metals in Patients at the Cologne University Hospital
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Neurodegenerative Diseases
Infections
Lead sponsor: University of Cologne
Sponsor class: OTHER
First posted: 2014-08-21
Enrollment: 3000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Sampling method: PROBABILITY_SAMPLE
Study population: neurodegenerative diseases infections

Brief summary: In this trial, concentrations of transition metals of interest are quantified in surplus cerebrospinal fluid (CSF) and blood serum samples. Quantification of the transition metals will be performed by inductively coupled plasma mass spectrometry (ICP-MS). The treating physicians as well as the patients will not be informed about the results of drug concentrations.

Detailed description: Samples used include:

Remaining portions of samples collected for diagnostic or therapeutic reasons (paired CSF and blood serum samples). No lumbar puncture will be done specifically for this protocol.

The objective of this study is to gain an overview about transition metals concentrations in blood serum and CSF in order to provide preliminary data on patients. The effect of neurodegenerative diseases on metals or the other way round will be assessed if possible.

Eligibility criteria: Inclusion Criteria: •

* The trial will include any patient (with various diseases, especially neurodegenerative diseases) who received a lumbar puncture.

Exclusion Criteria:

* • The lower age limit is 18 years. In concordance with the objective of the project there is no specific exclusion criteria.

Primary outcomes:
measure: Transition metal concentration
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Cologne
country: Germany
facility: Department of Pharmacology
state: Northrhine Westphalia
Study officials:
References:
Clinical trial NCT06859879: A Combined Supplementation of Rosemary and Daylily for Enhancing Sleep Quality in Middle-Aged Adults
Official title: Effects of 8-week Supplementation With Two Doses of Rosemary and Daylily on Sleep Quality, Circadian Rhythms, Energy Metabolism, and Biochemical Indices in Middle-Aged Adults: A Randomized, Placebo-Controlled Crossover Trial.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Sleep
Lead sponsor: University of Novi Sad, Faculty of Sport and Physical Education
Sponsor class: OTHER
First posted: 2025-03-05
Enrollment: 10
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This study aims to investigate the impact of supplementation with two different doses of Rosemary and Daylily herbal extract on various health outcomes in middle-aged adults. Over an eight-week period, the trial will assess improvements in sleep quality, circadian rhythms, energy metabolism, and relevant biochemical markers. The study employs a randomized, placebo-controlled, crossover design to evaluate the efficacy of these supplements in enhancing overall health and well-being.


Eligibility criteria: Inclusion Criteria:

* Age \> 50 years
* Trouble falling asleep \> 5 times a month (NHANES criteria)
* Body mass index 18.5-29.9 kg/m2
* Free of major chronic diseases or acute disorders
* Given written informed consent

Exclusion Criteria:

* History of dietary supplement use \> 2 weeks before the study commences
* Abnormal values for lab clinical chemistry (\> 2 SD)
* Unwillingness to return for follow-up analysis
* Participation in other clinical trials
* Moderate-to-heavy use of alcohol (\> 3 drinks per week)

Primary outcomes:
measure: Total sleep time
timeFrame: Change from baseline total sleep time at 8 weeks
Secondary outcomes:
measure: Melatonin
timeFrame: Change from baseline serum melatonin at 8 weeks
measure: Pittsburgh Sleep Quality Index (PSQI)
timeFrame: Change from baseline PSQI at 8 weeks
Other outcomes:
Locations:
city: Novi Sad
country: Serbia
facility: Applied Bioenergetics Lab at Faculty of Sport and PE
state: Vojvodina
Study officials:
References:
Clinical trial NCT06463379: The Efficacy of Intravenous Pulse in Attaining Remission in Refractory Juvenile Idiopathic Arthritis
Official title: The Efficacy of Intravenous Pulse in Attaining Remission in Refractory Juvenile Idiopathic Arthritis
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Refractory Juvenile Idiopathic Arthritis (Despite 2 DMARDs Still Active)
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2024-06-17
Enrollment: 215
Sex: ALL
Minimum age (years): 2
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Interventional phase 3 study aiming to unravel the value of pulse steroids in achieving remission or low disease activity in refractory active JIA

Detailed description: First group will receive 2 consecutive days intravenous pulse of 125 mg methylprednisolone.

Second group will not receive additional drugs. Assessment was done at baseline and every month for 3 months for both groups using Juvenile Arthritis Disease Activity Score (JADAS) and the American College of Rheumatology Pediatric 30, 50, and 70 response criteria (ACR Pedi. 30, 50, 70).

Eligibility criteria: Inclusion Criteria:

* Patients still active despite administration o 2 DMARDs

Exclusion Criteria:

* Other connective tissue diseases
* Endocrine disorders such as Thyroid disorders.

Primary outcomes:
measure: remission or low disease activity
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Al-Azhar University
Study officials:
References:
Clinical trial NCT01782079: L. Brevis CD2 Strain Persistence in Oral Cavity
Official title: Assessment of Probiotic Lactobacillus Brevis CD2 Strain Persistence in Oral Cavity. A Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Oral Health
Keywords: Lactobacillus brevis
Oral health
Bacterial adhesion
Lead sponsor: University of Roma La Sapienza
Sponsor class: OTHER
First posted: 2013-02-01
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The aim of this study is to select the optimal conditions for quantification in the oral cavity of Lactobacillus brevis CD2, a probiotic strain contained in a commercially available dietary supplement and to assess its persistency after oral administration. Different sets of primers for L. brevis detection will be tested in real-time PCR reactions to find optimal amplification efficiency and target specificity. Primers ability in the identification of L. brevis DNA will be assessed in a pilot study conducted on 12 healthy volunteers clinically free of oral pathologies. The subjects will take 3 tablets/day for 3 days and one tablet on the 4th day. Clinical samples (dorsal surface of tongue, first molar, vestibular fornix and saliva) will be collected at baseline (before beginning the trial), at T0 (in the morning before the assumption of the last tablet) and 3, 6, and 9 hours after taking the last tablet. The quantities of L. brevis DNA will be compared to the total number of bacteria present in the samples. The activity of the enzyme arginine deiminase, responsible for oral pH homeostasis (particularly abundant in the CD2 strain) will be also assessed in the saliva samples before and after treatment, by HPLC measurements.


Eligibility criteria: Inclusion Criteria:

* Age \> 18 years
* Healthy subjects with no oral cavity pathologies
* Written informed consent

Exclusion Criteria:

* Patients with oral diseases
* Patients with systemic diseases
* Celiac patients or subjects affected by allergic reactions to soy proteins
* Use of antibiotics or other probiotics

Primary outcomes:
measure: Quantification and persistency of Lactobacillus brevis CD2 after oral administration
timeFrame: 4 days
Secondary outcomes:
measure: Arginine deiminase activity
timeFrame: 4 days
Other outcomes:
Locations:
city: Roma
country: Italy
facility: Università La Sapienza
Study officials:
References:
Clinical trial NCT05337579: Combined Effects of Exercise Breaks and Rest Breaks on Fatigue and Musculoskeletal Discomfort in Static Workstation Office Workers
Official title: Combined Effects of Exercise Breaks and Rest Breaks on Fatigue and Musculoskeletal Discomfort in Static Workstation Office Workers
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Musculoskeletal Pain
Lead sponsor: Foundation University Islamabad
Sponsor class: OTHER
First posted: 2022-04-20
Enrollment: 42
Sex: ALL
Minimum age (years): 25
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Musculoskeletal discomfort and work fatigue has enormous impact on quality of personal and professional life and increases health related economic burden on country due to increased cost of healthcare and reduced productivity in work. Upper limb and neck pain complains are the most frequent when evaluated in computer workers. The incidence of musculoskeletal discomfort in office workers is as high as 50%. While fatigue is also common due to its high prevalence and its relationship with dysfunctional disorders in office workers. The objective of this study is to compare and determine the effects of exercise breaks, rest breaks and exercise along with rest breaks on Fatigue and Musculoskeletal discomfort in static workstation office workers


Eligibility criteria: Inclusion Criteria:

* Both male and female
* Age: 25-45 years
* Those static workstation office workers using computer for at least 6 hours per day.
* Static workstation office workers screened by ROSA.

Exclusion Criteria:

* Discomfort from non-musculoskeletal origin
* Recent history of trauma and receiving any kind of treatment for the current condition.
* Severe orthopedic disease
* Any mental and physiological illness that could interfere in the exercise.

Primary outcomes:
measure: Musculoskeletal Discomfort
timeFrame: 5th week
measure: Fatigue
timeFrame: 5th week
Secondary outcomes:
Other outcomes:
Locations:
city: Islamabad
country: Pakistan
facility: Foundation University
Study officials:
References: